Search

Lonny Yarmus, DO, MBA, has been appointed Head of the Division of Subspecialty Medicine in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). A physician-scientist and internationally recognized leader in interventional pulmonology and procedural innovation, Dr. Yarmus is widely known for his expertise in minimally invasive diagnostics and therapeutics, outcomes research, and multidisciplinary program development.

… Tuesday, March 10, 2026 Lonny Yarmus, DO, MBA , has been appointed Head of the Division of Subspecialty Medicine in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). A physician-scientist and internationally recognized leader in interventional pulmonology and procedural innovation

Experts at Memorial Sloan Kettering Cancer Center (MSK) have identified genome doubling in cancer and have correlated it to a worse prognosis across cancer types. Using MSK-IMPACT™ to analyze matched tumor and normal DNA, MSK researchers were able to identify an abnormality in tumors known as genome doubling. This doubling occurs in 28 percent of all cancers and could have significant implications for treatment options in the future.

… Monday, July 16, 2018 Bottom Line: Experts at Memorial Sloan Kettering Cancer Center (MSK) have identified genome doubling in cancer and have correlated it to a worse prognosis across cancer types. Using MSK-IMPACT™ to analyze matched tumor and normal DNA, MSK researchers were able to identify an abnormality

This year, the Robbins Family Awards for Nursing Excellence at Memorial Sloan Kettering held a deeper significance.

… Wednesday, May 12, 2021 This year, the Robbins Family Awards for Nursing Excellence at Memorial Sloan Kettering held a deeper significance. By early April 2020, the number of COVID-19 patients being treated at Memorial Sloan Kettering had quickly surpassed 100. Personal protective equipment in New York

Learn more about from MSK experts about what the latest research on the connection between eating sugar and cancer risk.

… Thursday, April 10, 2025 One of the most misunderstood topics in the complex interplay of food, obesity, and cancer is sugar. The internet is full of misrepresentations and half-truths that lead many people to incorrectly believe that sugar directly causes cancer — or even that cancer can be treated

A protein on certain immune cells is a promising target for making immunotherapy more effective against breast cancer.

… Tuesday, November 29, 2016 Summary Immunotherapy has been less effective against breast cancer than other cancers. Researchers think regulatory T (Treg) cells are restraining the immune system from mounting an adequate attack against breast tumors. New research identifies a protein in specific Treg cells

Discover how Memorial Sloan Kettering’s Multidisciplinary Brain Metastasis Clinic is revolutionizing treatment for metastatic brain tumors.

… Thursday, July 1, 2021 A busy real estate broker and married mother of three, Susan van der Griend is an optimist by nature, used to making things happen and moving on. When she was diagnosed with melanoma in 2017, she decided to be treated near her home in Connecticut. But a positive outlook didn’t

Memorial Sloan Kettering experts are available to comment on new research presented at the American Association for Cancer Research 2016 Annual Meeting including immunotherapy and CAR T cells, exercise oncology, precision medicine and more. For more information and to set up interviews or access photos, email Nicole H. McNamara at [email protected].

… Friday, April 15, 2016 Thousands of oncology experts from around the world will gather in New Orleans from April 16 - 20 for the American Association for Cancer Research 2016 Annual Meeting. This year’s theme, “Delivering Cures Through Cancer Science,” reinforces the inextricable link between research

New data from an international, multicenter Phase III clinical trial has found that the experimental targeted therapy everolimus (RAD001) significantly delays cancer progression in patients with metastatic kidney cancer whose disease had worsened on other treatments.

… Friday, May 16, 2008 New data from an international, multicenter Phase III clinical trial has found that the experimental targeted therapy everolimus (RAD001) significantly delays cancer progression in patients with metastatic kidney cancer whose disease had worsened on other treatments. The study was

MSK's Robert Motzer presented positive data from a phase III randomized study that assessed two different treatment combinations as first-line therapies that may benefit people with advanced kidney cancer.

… Monday, February 15, 2021 Update: On August 11, 2021, the FDA approved pembrolizumab (Keytruda®) plus lenvatinib (Lenvima®) for first-line treatments for patients with advanced renal cell carcinoma (RCC). Memorial Sloan Kettering Cancer Center (MSK) physicians and scientists presented new research at

Pediatric oncologists from around the world will gather in Lyon, France, from October 23 through 26, for the International Society of Paediatric Oncology’s annual meeting. Featuring new research and important discoveries — many led by MSK Kids researchers — the meeting will highlight the latest in the fields of pediatric oncology, including blood cancer, sarcoma, Wilms’ tumor, genomics, radiation oncology, and neuroblastoma.

… Tuesday, October 22, 2019 Pediatric oncologists from around the world will gather in Lyon, France, from October 23 through 26, for the International Society of Paediatric Oncology’s annual meeting. Featuring new research and important discoveries — many led by MSK Kids researchers — the meeting will